References
- Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract Res Clin Haematol 2003;16:41–56.
- Piris M, Foucar K, Mollejo M, Campo E, Falini B. Splenic B-cell lymphoma/leukemia unclassifiable. World Health Organization classification of tumors of haematopoietic and lymphoid tissuesIn: Swerdlow SH, Campo E, Harris NL, et al., editors. Lyon: IARC Press; 2008. pp 191–192.
- Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 2001;15:184–186.
- Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 2006;32:365–376.
- Sainati L, Matutes E, Mulligan S, A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood 1990;76:157–162.
- Robak T, Błasińska-Morawiec M, Błoński J, 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999;62:49–56.
- Palomera L, Domingo JM, Sola C, Azaceta G, Calvo MT, Gutierrez M. Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases. Haematologica 2002;87:107–108.
- Robak T. Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 2011; 37:3–10.
- Sasaki M, Sugimoto K, Mori T, Karasawa K, Oshimi K. Effective treatment of a refractory hairy cell leukemia variant with splenic pre-irradiation and alemtuzumab. Acta Haematol 2008;119:48–53.
- Quach H, Januszewicz H, Westerman D. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica 2005;90(Suppl.): ECR26.
- Narat S, Gandla J, Dogan A, Mehta A. Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma 2005;46:1229–1232.
- Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009;23:1–13.
- Kreitman RJ, Wilson WH, Bergeron K, Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001;345:241–247.
- Kreitman RJ, Tallman MS, Coutre SE, Phase I trial of recombinant immunotoxin CAT-8015 (HA22) in multiply relapsed hairy cell leukemia. J Clin Oncol 2010;28(15 Suppl.): Abstract 6523.